Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-10-30
2007-10-30
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S231500, C514S326000, C514S422000, C514S444000, C544S146000, C546S213000, C548S527000, C548S950000, C549S059000, C549S060000
Reexamination Certificate
active
10924180
ABSTRACT:
The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.
REFERENCES:
patent: 5019587 (1991-05-01), Von Der Saal et al.
patent: 5932599 (1999-08-01), Godel et al.
patent: 5962490 (1999-10-01), Chan et al.
patent: 5998439 (1999-12-01), Maynard et al.
patent: 6335334 (2002-01-01), Schindler et al.
patent: 6395759 (2002-05-01), Thompson et al.
patent: 6420567 (2002-07-01), Wu et al.
patent: 6632839 (2003-10-01), Neumann
patent: 2005/0049286 (2005-03-01), Wu et al.
patent: 0 344 634 (1989-05-01), None
patent: 0 533 266 (1992-09-01), None
patent: 0 533 267 (1992-09-01), None
patent: 0 533 268 (1992-09-01), None
patent: 0 815 861 (1998-01-01), None
patent: 1 104 763 (1999-08-01), None
patent: WO 94/22807 (1994-10-01), None
patent: WO/96/31492 (1996-10-01), None
patent: WO98/13366 (1998-04-01), None
patent: WO 00/27820 (2000-05-01), None
patent: WO 01/49289 (2001-07-01), None
patent: WO 02/28353 (2002-04-01), None
patent: WO 02/089740 (2002-11-01), None
patent: WO 02/089785 (2002-11-01), None
patent: WO 02/089792 (2002-11-01), None
patent: WO 02/089793 (2002-11-01), None
patent: WO 02/090337 (2002-11-01), None
patent: WO 02/090348 (2002-11-01), None
patent: WO 02/090353 (2002-11-01), None
patent: WO 03/099773 (2003-12-01), None
patent: WO 03/099773 (2003-12-01), None
patent: WO 2004/026836 (2004-04-01), None
patent: WO 2004/046092 (2004-06-01), None
Patani et al. “Bioisosterism: A Rational Approach in Drug Design” Chem. Rev. 1996, 3147-3176.
Wu et al. “Endothelin Antagonists: Substituted Mesitylcarboxamides with High Potency and Selectivity for ETa Receptors” J. Med. Chem. 1999, Vole 42, pp. 4485-4499.
Wu, et al., “Endothelin Antagonists: Substituted Mesitylcarboxamides with High Potency and Selectivity for ETAReceptors”; J. Med. Chem. 1999, 42, 4485-4499.
Silverman, R.B., “The Organic Chemistry of Drug Design and Drug Action” pp. 15-22 (1992).
Biediger Ronald
Chen Jie
Gao Daxin
Market Robert V.
Wu Chengde
Encysive Pharmaceuticals Inc.
Jones Day
Kosack Joseph R.
McKane Joseph K.
LandOfFree
Phenylenediamine urotensin-II receptor antagonists and CCR-9... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phenylenediamine urotensin-II receptor antagonists and CCR-9..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenylenediamine urotensin-II receptor antagonists and CCR-9... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3834545